Conclusion
The uptake of infliximab biosimilars has been slow at an academic medical center compared with a nearby VAMC, where financial savings are realized by the institution from biosimilar use. Slow adoption of biosimilar medications may impact the rates of decline in costs.
Refer to the full study for all source material.
Excerpted and adapted from:
Baker JF, Leonard CE, Lo Re, V III, et al. Biosimilar uptake in academic and Veterans Health Administration settings: Influence of institutional incentives. Arthritis Rheumatol. 2020 Jul;72(7).